How deadly is Prostate cancer?

['Welisi hɔɔlʋʋ kʋnɛ']

Ɛzɩma tɩyɛ calɩm hosi lɩzʋʋ kʋdɔŋ kpa ɛyaa sakɩyɛ?

Kʊdɔŋ ŋgʊ kɩkɛ naalɛ ŋgʊ ŋgʊ ɛyaa ɖɔʊ taa kedeŋga kpeekpe taa nɛ pɩnaɣ 2018 taa pana ɛyaa kɩfama ɛzɩ miliyɔɔnaa 1,276 yɔ nɛ pɩwɩlɩɣ se ɛyaa kʊdɔmɩŋ kpeekpe taa lɛ, ɛyaa 7,1% yɔɔ kɛ pɩlɩna.

Pɩtɛ kɩgalʊʊ ŋgʊ kɩ-taa pana ɛyaa mba pasɩkɩna kʊdɔŋ ŋgʊ yɔ pɛɖɛ ɛzɩ ɛyaa 37005 yɔ pɩnaɣ 2018 taa.

Ɛlɛ, kʋdɔŋ piye nɖɩ ɖɩ-sɩkɩna ɛyaa yɔ, ɖɩfɛyɩ kɩmaŋ paa ɛjaɖɛ nɖɩ ɖɩ-taa.

Naajeeriya ɛjaɖɛ taa lɛ, ɛyaa ɛzɩ 100 000 yɔɔ lɛ, 32,8 yɔɔdɩɣna-kʋ nɛ 16,3 ñasɩkɩna-kʋ.

Ɛyaa mba pasɩkɩ yɔ, pa-taa lɛ, ɛyaa mba pɛwɛ Amerika hayo kiŋ yɔ, pɛcɛzɩ tam nabʋlɛ.

Kʋdɔŋ ŋgʋ, kɩ-tɛ ɖɛʋ nɛ ɛsɩndaa, ɛzɩma patɩtɩlɩ labʋ nɛ kʋdɔmɩŋ ɛnɩ ɩtaakɔɔ nɛ ɛyaa sakɩyɛ sɩkɩ yɔ, nɛ ɛzɩma patɩtɩlɩ ɖɔɖɔ ɛzɩma pawaɣ kʋdɔmɩŋ ɛnɩ yɔ, piyeba nɛ ɛyaa sakɩyɛ sɩkɩ kʋdɔŋ ŋgʋ kɩ-taa Naajeeriya ɛjaɖɛ taa.

Etaazuunii ɛjaɖɛ taa lɛ, canatʋ kʋdɔŋ kɩlɩna ɛyaa kʋʋ kʋdɔŋ piye nɖɩ ɖɩkʋʋ ɛyaa yɔ.

Kpaɣnɩ pɩnzɩ 1990 waa ɖɩbazɩyɛ taa, kʋdɔŋ ŋgʋ kɩkpa ɛyaa yɔ, kɩɩwɛɛ nɛ kɩkpaɣ ɖoŋ kpaʋ yɔɔ, ɛlɛ kɩpɩsɩɣ kala sɔsɔna ɛyaa wezuu caɣʋ taa.

Kedeŋa kpeekpe yɔɔ lɛ, tɔnʊʊ taa alaafɩya hɔɔlʊʊ taa lɛ, kʊdɔŋ ŋgʊ kɩkɛ kʊdɔŋ ŋgʊ kɩkɩla ɛyaa sakɩyɛ sɩm yɔ, kɔzɩ kɔzɩ ageeta wena a-taa ɖɔkɔtɔ naa fɛyɩ yɔ.

Ɛlɛ ye kʋdɔŋ ŋgʋ kɩkpa ɛyʋ lɔŋ nɛ pawaa-kʋ yɔ, pɩsɩɣnɩ-ɩ nɛ ɛ-kʋdɔŋ cɛ nɛ ɛsɩ.

['Takayɩhatʋ ndʋ tɩtamsɩna \\ yɔ']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.

Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.

Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.

Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.

Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.

['Tɔm ndʋ tɩ-yɔɔ ɖitisiɣ yɔ: ɖɔkɔtɔ']

['Ye ŋwobi intɛrnɛɛtɩ lone ɖɩnɛ ɖɩ-yɔɔ yɔ, ŋpɩzɩɣ nɛ ŋkpɛlɩkɩ tɔm sakɩyɛ ɖɩ-yɔɔ.']

['Pɩtɩpɔzɩ se patɩŋnɩ tɔm ndʋ pama takayaɣ kanɛ ka-taa yɔ tɩ-yɔɔ nɛ pañɩnɩ kʋdɔŋ nakʋyʋ yaa pawaa-kʋ.']

['Tɩlɩ camɩyɛ se ordinatɛɛrɩ yɔɔ tɔm ndʋ pɔpɔzʋʋ yɔ, tɩ-yɔɔ cosuu wɛ kaɖɛ, kɔzɩ kɔzɩ alɩwaatʋ ndʋ tɩ-taa pɔpɔzʋʋ tɔm natʋyʋ nɛ tɩ-taa tɔm pee tɩɖɔɔ yɔ.']

['Paa ɛzɩmtaa lɛ, pɔzɩ lɔŋ tasʋʋ fɛɖʋ weyi ɛsɩm ñɔ-yɔɔ tɔm sakɩyɛ yɔ nɛ ɛyɔɔdɩ-ŋ kʋdɔŋ ŋgʋ ŋwɛna yɔ kɩ-tɔm. Taayele nɛ lɔŋ tasʋʋ mbʋ fɛɖʋ ɛnʋ ɛha-ŋ yɔ, pɩɖɛɛ ñɔ-yɔɔ yaa ŋyele-pʋ ñɩnʋʋ mbʋ pʋyɔɔ yɔ ŋkalɩ tɔm natʋyʋ intɛrnɛɛtɩ lone ɖɩnɛ ɖɩ-yɔɔ. Ye ŋmaɣzɩɣ se pɩwɩɣ-ŋ yɔ, yaa ɛyaa 911 yaa ŋwolo ɖɔkɔtɔ ŋgʋ kɩñɔtɩnɩ-ŋ yɔ kɩ-taa kpaagbaa.']

['Takayɩhatʋ ndʋ tɩtamsɩna \\ Paɣtʋ \\ yɔ']

['Digital Millennium Copyright Act 1998 ñɩŋgʋ, 17 U.S.C. § 512 (DMCA) haɣ waɖɛ mba pɛwɛnɩ waɖɛ se pala tʋmɩyɛ intɛrnɛɛtɩ yɔɔ yɔ se pala mbʋ pɩkaɖɩɣnɩ waɖɛ nɖɩ pɛwɛna Etaazuunii ɛjaɖɛ taa yɔ.']

['Ye ŋmaɣzɩɣ se tɔm natʋyʋ yaa wonuu nakʋyʋ yɔɔ pama tɔm intɛrnɛɛtɩ lone ɖɩnɛ ɖɩ-yɔɔ yaa intɛrnɛɛtɩ lone ɖɩnɛ ɖɩ-yɔɔ nɛ pɩkaɖɩɣnɩ ña-paɣtʋ yɔ, ña-maɣmaɣ yaa weyi ɛsɩɣ-ŋ tʋmɩyɛ yɔ, ŋpɩzɩɣ nɛ ŋtiyini-ɖʋ takayaɣ nɛ ŋpɔzɩ se ɖɩlɩzɩ tɔm ndʋ yaa wonuu ŋgʋ yaa ɖitaayele nɛ nɔɔyʋ tɩlɩ-kʋ.']

['Pɩwɛɛ se pama takayaɣ nɛ petiyini ordinatɛɛrɩ yɔɔ.']

['DMCA paɣtʋ pɔzʋʋ se ye ŋnawa se nɔɔyʋ tɩma takayaɣ nakɛyɛ yɔ, ŋma tɔm tʋnɛ: (1) takayaɣ ŋga ŋnawa se nɔɔyʋ tɩma-kɛ yɔ kɔ-yɔɔ tɔm; (2) takayaɣ ŋga kɔ-yɔɔ pamawa se nɔɔyʋ tɩma takayaɣ nakɛyɛ yɔ kɔ-yɔɔ tɔm nɛ tɔm ndʋ tɩsɩɣnɩ-ɖʋ se ɖɩtɩlɩ ɖenɖe ŋnaɣ takayaɣ ŋga yɔ; (3) ña-hɩɖɛ, kaŋgalaafu mayaɣ nɛ intɛrnɛɛtɩ mayaɣ; (4) ŋyɔɔdɩ kpayɩ se ŋwɛnɩ tisuu se takayaɣ ŋga ŋnawa se nɔɔyʋ tɩma-kɛ yɔ, pɩtɩkɛ weyi ɛtɩnɩ takayaɣ ŋga yɔ ɛ-maɣmaɣ ɛlɩzɩnɩ-kɛ, yaa ɛ-tʋmlaɖʋ nɔɔyʋ lɩzɩnɩ-kɛ, yaa se paɣtʋ natʋyʋ ɛɛhaɣ nʋmɔʋ se palabɩnɩ-kɛ tʋmɩyɛ.']

['(5) Ye ŋlabɩ mbʋ yɔ, ŋpɩzɩɣ nɛ ŋcɛtɩnɩ ñɔ-tɔm yɔɔ nɛ ŋyɔɔdɩ se tɔm ndʋ pama takayaɣ ŋga ka-taa yɔ tɩkɛ toovenim nɛ ŋwɛnɩ waɖɛ se ŋlʋ nɛ ŋwa mba payʋsʋʋ se pɛwɛɛkɩ ña-takayaɣ yɔ.']

['Nɛ (6) ye nɔɔyʋ ɛtɩnɩ takayaɣ nakɛyɛ yɔɔ tɔm yɔ, pɩwɛɛ se ɛñɩɣ nesi takayaɣ ŋga kɔ-yɔɔ.']

['Ye patɩyɔɔdɩ tɔm ndʋ tɩ-tɩŋa yɔ, pɩpɩzɩɣ nɛ pɩkɔnɩ tɔm hʋʋ kaɖɛ.']

['Ɛyʋ weyi ŋkatɩɣ yɔ']

['Ye ŋwɛnɩ tɔm natʋyʋ yaa ŋñɩnɩɣ se ŋtasɩ tɔm natʋyʋ yɔ, ɖitendi-ŋ ma-ɖʋ takayaɣ.']

How deadly is prostate cancer?

Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.

The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.

However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.

In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.

This is more than double the death rate in North America.

Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.

In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.

The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.

Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.

However, early detection and treatment can significantly improve outcomes and reduce mortality rates.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.